NCT06109558View on ClinicalTrials.gov

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

July 30, 2027

Conditions
Non Small Cell Lung CancerRET Gene MutationMET AmplificationEGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG

LMV-12(HE003)

1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER